Abstract
Background. Activation of neuroendocrine factors plays a major role in the pathophysiology and progression of heart failure. The aim of the present study was 1) to assess the clinical correlates of elevated plasma natriuretic peptides [atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP)] and Big endothelin-1 in a population of 180 ambulatory patients from the Italian registry of heart failure (Italian Network on Congestive Heart Failure, IN-CHF) in 22 clinical centers, 2) to assess the within-patient variability of plasma BNP concentration, and 3) to evaluate the analytical agreement for BNP determination between a core laboratory and local sites. Methods. ANP and BNP were measured with specific immunoradiometric methods, Big endothelin-1 with an enzyme immunoassay. Results. Elevated BNP was associated with severe mitral valve regurgitation (odds ratio 8.546, 95% confidence interval 1.879-38.510, p = 0.0052); high circulating concentrations of ANP and BNP were found in older patients, and in patients with higher NYHA functional class or reduced left ventricular ejection fraction. Elevated plasma concentration of Big endothelin-1 was a strong and independent predictor of atrial fibrillation (odds ratio 4.001, 95% confidence interval 1.531-10.454, p = 0.0047). Plasma concentration of BNP was reasonably stable at 3-month interval in patients with mild-to-moderate heart failure (mean between-visit difference -1.5 ± 45 pg/ml, n = 96). There was a satisfactory analytical agreement between the central laboratory and sites, over a broad range of concentrations (2-1133 pg/ml, n = 283) with a slope for the best line fitted by linear regression of 1.09 (r2 = 0.96). Conclusions. BNP assay may become an appropriate tool for routine clinical practice in patients with congestive heart failure.
| Original language | English |
|---|---|
| Pages (from-to) | 282-288 |
| Number of pages | 7 |
| Journal | Italian Heart Journal |
| Volume | 1 |
| Issue number | 4 |
| Publication status | Published - 2000 |
Fingerprint
Keywords
- Atrial natriuretic peptide
- Big endothelin-1
- Brain natriuretic peptide
- Heart failure
- Hormones
- Natriuretic peptides
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Clinical correlates of elevated plasma natriuretic peptides and Big endothelin-1 in a population of ambulatory patients with heart failure. A substudy of the Italian Network on Congestive Heart Failure (IN-CHF) registry. / Masson, S.; Gorini, M.; Salio, M.; Lucci, D.; Latini, R.; Maggioni, A. P.
In: Italian Heart Journal, Vol. 1, No. 4, 2000, p. 282-288.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical correlates of elevated plasma natriuretic peptides and Big endothelin-1 in a population of ambulatory patients with heart failure. A substudy of the Italian Network on Congestive Heart Failure (IN-CHF) registry
AU - Masson, S.
AU - Gorini, M.
AU - Salio, M.
AU - Lucci, D.
AU - Latini, R.
AU - Maggioni, A. P.
PY - 2000
Y1 - 2000
N2 - Background. Activation of neuroendocrine factors plays a major role in the pathophysiology and progression of heart failure. The aim of the present study was 1) to assess the clinical correlates of elevated plasma natriuretic peptides [atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP)] and Big endothelin-1 in a population of 180 ambulatory patients from the Italian registry of heart failure (Italian Network on Congestive Heart Failure, IN-CHF) in 22 clinical centers, 2) to assess the within-patient variability of plasma BNP concentration, and 3) to evaluate the analytical agreement for BNP determination between a core laboratory and local sites. Methods. ANP and BNP were measured with specific immunoradiometric methods, Big endothelin-1 with an enzyme immunoassay. Results. Elevated BNP was associated with severe mitral valve regurgitation (odds ratio 8.546, 95% confidence interval 1.879-38.510, p = 0.0052); high circulating concentrations of ANP and BNP were found in older patients, and in patients with higher NYHA functional class or reduced left ventricular ejection fraction. Elevated plasma concentration of Big endothelin-1 was a strong and independent predictor of atrial fibrillation (odds ratio 4.001, 95% confidence interval 1.531-10.454, p = 0.0047). Plasma concentration of BNP was reasonably stable at 3-month interval in patients with mild-to-moderate heart failure (mean between-visit difference -1.5 ± 45 pg/ml, n = 96). There was a satisfactory analytical agreement between the central laboratory and sites, over a broad range of concentrations (2-1133 pg/ml, n = 283) with a slope for the best line fitted by linear regression of 1.09 (r2 = 0.96). Conclusions. BNP assay may become an appropriate tool for routine clinical practice in patients with congestive heart failure.
AB - Background. Activation of neuroendocrine factors plays a major role in the pathophysiology and progression of heart failure. The aim of the present study was 1) to assess the clinical correlates of elevated plasma natriuretic peptides [atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP)] and Big endothelin-1 in a population of 180 ambulatory patients from the Italian registry of heart failure (Italian Network on Congestive Heart Failure, IN-CHF) in 22 clinical centers, 2) to assess the within-patient variability of plasma BNP concentration, and 3) to evaluate the analytical agreement for BNP determination between a core laboratory and local sites. Methods. ANP and BNP were measured with specific immunoradiometric methods, Big endothelin-1 with an enzyme immunoassay. Results. Elevated BNP was associated with severe mitral valve regurgitation (odds ratio 8.546, 95% confidence interval 1.879-38.510, p = 0.0052); high circulating concentrations of ANP and BNP were found in older patients, and in patients with higher NYHA functional class or reduced left ventricular ejection fraction. Elevated plasma concentration of Big endothelin-1 was a strong and independent predictor of atrial fibrillation (odds ratio 4.001, 95% confidence interval 1.531-10.454, p = 0.0047). Plasma concentration of BNP was reasonably stable at 3-month interval in patients with mild-to-moderate heart failure (mean between-visit difference -1.5 ± 45 pg/ml, n = 96). There was a satisfactory analytical agreement between the central laboratory and sites, over a broad range of concentrations (2-1133 pg/ml, n = 283) with a slope for the best line fitted by linear regression of 1.09 (r2 = 0.96). Conclusions. BNP assay may become an appropriate tool for routine clinical practice in patients with congestive heart failure.
KW - Atrial natriuretic peptide
KW - Big endothelin-1
KW - Brain natriuretic peptide
KW - Heart failure
KW - Hormones
KW - Natriuretic peptides
UR - http://www.scopus.com/inward/record.url?scp=0033781114&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033781114&partnerID=8YFLogxK
M3 - Article
C2 - 10824729
AN - SCOPUS:0033781114
VL - 1
SP - 282
EP - 288
JO - Italian Heart Journal
JF - Italian Heart Journal
SN - 1129-471X
IS - 4
ER -